A team from the Broad Institute of MIT and Harvard, along with Harvard University and the Howard Hughes Medical Institute, has made exciting strides in using a gene-editing tool called prime editing to tackle the mutation responsible for cystic fibrosis in human lung cells. This innovative approach offers a more precise and safer alternative to traditional CRISPR methods, significantly lowering the chances of unintended changes to the genome. Cystic fibrosis is a genetic diso

Lenmeldy, a groundbreaking gene therapy developed by Orchard Therapeutics, has recently received FDA approval, making it the first and only treatment available for children with Metachromatic Leukodystrophy (MLD), a rare genetic disorder that severely affects the brain. Metachromatic Leukodystrophy is a rare lysosomal storage disorder caused by mutations in the ARSA and/or PSAP genes. These mutations result in the accumulation of sulfatide, leading to the degeneration of esse

The AK-OTOF-101 clinical trial by Akouos, Inc., a subsidiary of Lilly & Co., brings renewed hope to children suffering from congenital deafness through innovative AAV-based gene therapy. This pioneering research is taking place at The Children's Hospital of Philadelphia, which is leading the charge in developing effective treatments for this challenging condition. The clinical trial utilizes adeno-associated virus (AAV) vectors to deliver the OTOF gene, which encodes the otof